Closely held ENA Respiratory of Australia initiated a Phase 1 human safety study of INNA-051, being developed to activate innate immunity in the nose, the primary entry portal of most respiratory viral infections. A...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported that all primary endpoints were met in its Phase 2a AMBITION clinical trial in patients with non-alcoholic steatohepatitis (NASH). The Phase 2a trial was designed to...
Advaxis (NASDAQ:ADXS) and closely held Biosight of Israel entered into a definitive merger agreement, with shareholders of Biosight becoming the majority holders of the combined company. Advaxis will be renamed Biosight...
Adam Cutler Closely-held Q32 Bio appointed Adam Cutler as chief financial officer, with responsibility for all aspects of its financial strategy and operations. Mr. Cutler has more than 20 years of experience in...
UNITY Biotechnology (NASDAQ:UBX) announced positive data from its Phase 1 safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet age-related macular degeneration (AMD) for...
Titan Pharmaceuticals (NASDAQ:TTNP) reported that an in vivo study of its ProNeura-based human kappa-opioid receptor agonist, TP-2021, implant in an established itch-induced mouse model has demonstrated the...
Closely held Talkiatry, a leading mental health care provider that connects people with high-quality psychiatric care via telehealth or in-person, appointed Jared Camins as chief technology officer.
A peer-reviewed paper authored by clinicians and researchers from Germany’s ALTA Klinik and the University Hospital, LMU Munich, and published in Urologic Oncology illustrates that Profound Medical’s...
atai Life Sciences (NASDAQ:ATAI) priced an initial public offering of 15 million common shares at $15 each for gross proceeds of $225-million. In its first day of trading on June 18, the stock jumped $4.45, or 29%, to...
A $47-million series A financing from Versant Ventures and RA Capital Management launched LENZ Therapeutics, with a lead late-stage clinical program for presbyopia. Proceeds from the financing will be used to progress...